Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SFRP4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SFRP4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SFRP4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SFRP4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00900902 | Endometrium | AEH | negative regulation of canonical Wnt signaling pathway | 28/2100 | 137/18723 | 1.17e-03 | 1.01e-02 | 28 |
GO:00717722 | Endometrium | AEH | response to BMP | 32/2100 | 165/18723 | 1.38e-03 | 1.16e-02 | 32 |
GO:00717732 | Endometrium | AEH | cellular response to BMP stimulus | 32/2100 | 165/18723 | 1.38e-03 | 1.16e-02 | 32 |
GO:00456823 | Endometrium | AEH | regulation of epidermis development | 16/2100 | 65/18723 | 1.81e-03 | 1.44e-02 | 16 |
GO:00510905 | Endometrium | AEH | regulation of DNA-binding transcription factor activity | 69/2100 | 440/18723 | 2.51e-03 | 1.87e-02 | 69 |
GO:19040195 | Endometrium | AEH | epithelial cell apoptotic process | 24/2100 | 121/18723 | 3.81e-03 | 2.60e-02 | 24 |
GO:00456043 | Endometrium | AEH | regulation of epidermal cell differentiation | 14/2100 | 58/18723 | 4.12e-03 | 2.73e-02 | 14 |
GO:00900922 | Endometrium | AEH | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 43/2100 | 256/18723 | 4.47e-03 | 2.93e-02 | 43 |
GO:00085447 | Endometrium | AEH | epidermis development | 52/2100 | 324/18723 | 5.00e-03 | 3.14e-02 | 52 |
GO:0043271 | Endometrium | AEH | negative regulation of ion transport | 29/2100 | 160/18723 | 6.16e-03 | 3.70e-02 | 29 |
GO:003011113 | Endometrium | EEC | regulation of Wnt signaling pathway | 74/2168 | 328/18723 | 1.03e-08 | 6.47e-07 | 74 |
GO:001605513 | Endometrium | EEC | Wnt signaling pathway | 90/2168 | 444/18723 | 6.65e-08 | 3.50e-06 | 90 |
GO:019873813 | Endometrium | EEC | cell-cell signaling by wnt | 90/2168 | 446/18723 | 8.25e-08 | 4.23e-06 | 90 |
GO:006082813 | Endometrium | EEC | regulation of canonical Wnt signaling pathway | 56/2168 | 253/18723 | 1.18e-06 | 3.90e-05 | 56 |
GO:006007013 | Endometrium | EEC | canonical Wnt signaling pathway | 61/2168 | 303/18723 | 1.05e-05 | 2.25e-04 | 61 |
GO:000689815 | Endometrium | EEC | receptor-mediated endocytosis | 51/2168 | 244/18723 | 1.89e-05 | 3.50e-04 | 51 |
GO:003017713 | Endometrium | EEC | positive regulation of Wnt signaling pathway | 34/2168 | 140/18723 | 1.89e-05 | 3.50e-04 | 34 |
GO:000717814 | Endometrium | EEC | transmembrane receptor protein serine/threonine kinase signaling pathway | 68/2168 | 355/18723 | 1.90e-05 | 3.50e-04 | 68 |
GO:003010014 | Endometrium | EEC | regulation of endocytosis | 45/2168 | 211/18723 | 3.40e-05 | 5.78e-04 | 45 |
GO:004825913 | Endometrium | EEC | regulation of receptor-mediated endocytosis | 28/2168 | 110/18723 | 4.07e-05 | 6.78e-04 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SFRP4 | SNV | Missense_Mutation | rs748182253 | c.785N>A | p.Arg262His | p.R262H | Q6FHJ7 | protein_coding | tolerated(0.16) | possibly_damaging(0.616) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
SFRP4 | SNV | Missense_Mutation | | c.722N>G | p.Ser241Cys | p.S241C | Q6FHJ7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SFRP4 | SNV | Missense_Mutation | rs140561432 | c.514C>T | p.Arg172Cys | p.R172C | Q6FHJ7 | protein_coding | tolerated(0.11) | benign(0.28) | TCGA-D8-A27W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
SFRP4 | SNV | Missense_Mutation | | c.951G>C | p.Lys317Asn | p.K317N | Q6FHJ7 | protein_coding | tolerated_low_confidence(0.53) | benign(0) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SFRP4 | SNV | Missense_Mutation | | c.653N>G | p.Val218Gly | p.V218G | Q6FHJ7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
SFRP4 | insertion | Frame_Shift_Ins | novel | c.77_78insAAAGGGAGCCTTCGATGATGTTTGCATTTATAGT | p.Val27LysfsTer117 | p.V27Kfs*117 | Q6FHJ7 | protein_coding | | | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SFRP4 | deletion | Frame_Shift_Del | novel | c.687delN | p.Ile230SerfsTer36 | p.I230Sfs*36 | Q6FHJ7 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
SFRP4 | SNV | Missense_Mutation | novel | c.105G>A | p.Met35Ile | p.M35I | Q6FHJ7 | protein_coding | deleterious(0.01) | benign(0.289) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SFRP4 | SNV | Missense_Mutation | | c.1017G>C | p.Lys339Asn | p.K339N | Q6FHJ7 | protein_coding | deleterious_low_confidence(0) | benign(0.115) | TCGA-C5-A7X8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SFRP4 | SNV | Missense_Mutation | | c.83G>A | p.Arg28His | p.R28H | Q6FHJ7 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |